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Results: A total of 541 outpatients (71.1% consent, 73.1% completion) and
124 professionals (47.1% response) participated, including 336 (62.0%)
oncology outpatients and 67 (52.3%) professionals with an interest in
cancer. On average, outpatients selected 2.4 (median = 1, IQR = 1–3) initia-
tives; professionals selected 10.7 (median = 10, IQR = 6–15) initiatives.
Compared to outpatients, a greater proportion of professionals selected each
initiative (p < 0.001). Information-based initiatives were included in both
groups’ top ten most-frequently selected. Initiatives relating to service acces-
sibility were included in outpatients’ top ten only, patient communication
and care coordination were only included in professionals’ top ten.
Conclusions: Outpatients selected few improvement targets potentially
reducing the complexity of service change and resources required. Compara-
tively, professionals indicated a greater degree of change is needed and
emphasised aspects related to daily practise.
Translational research aspect (T3): Government policy mandates patient
engagement in health evaluation and professionals’ support is essential to
sustained quality improvement. However, patients and professionals vary in
the degree and type of change desired. A collaborative model is needed to
translate both groups’ preferences into improved chronic disease care.
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Background: With many anticancer drugs, both interpatient and intrapa-
tient pharmacokinetic (PK) or pharmacodynamic variability can account for
treatment failure or excess toxicity, due to under- or over-dosing. Tailoring
drug treatment regimens can provide better outcomes by maximising drug
benefit and minimising toxicity, especially in patients with extreme pheno-
types such as obesity, advanced age or organ dysfunction. This is specifically
so with newer oral therapies which have pharmacokinetics affected by diet
in addition to changing PK parameters during treatment.
Aims: To establish Therapeutic Drug Monitoring (TDM) facility at Calvary
Mater Newcastle Hospital.
Methods: HPLC, LC-MS and LC-MS/MS methodologies have been devel-
oped to measure various chemotherapy drugs and their metabolites in
patient blood samples.
Results: Our validated methodologies can support clinical decisions by mea-
suring several chemotherapy drugs and their metabolites in patient samples:
mitotane, fluoropyrimidines, anthracyclines, taxanes, vincas, uracil, and
some tyrosine kinase inhibitors (pazopanib, sunitinib). In adrenocortical
cancer, we used TDM of mitotane and metabolites in 15 patients to facilitate
achievement of ideal concentrations (14–20 μg/ml) in 11 patients and
support dose-reduction in 6 patients with toxic levels. In a phase I study of
a new formulation of 5FU and folinic acid (Deflexifol), PK parameters in
each patient are determined to achieve rapid dose escalation. In adjuvant
therapy of breast cancer, we will monitor blood levels of anthracyclines,
taxanes, 5FU and cyclophosphamide to determine if PK differences explain
worse outcomes in obese as compared to normal weight women. In renal
and other cancers, we will assess PK of pazopanib and sunitinib to identify
patients needing dose modification.
Conclusions: TDM is an under-utilised translational tool in cancer chemo-
therapy, with significant capacity to optimise dosing and explain variability
in outcomes. This facility can be adapted for other drugs and clinical
situations.
Translational research aspect: This project (T2-T3) leads to clinical deci-
sions for dose adjustments.
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Background: Smoking prevalence among Indigenous pregnant women is
high at 49%. Evidence-based smoking cessation interventions have not been
effectively translated into the maternal Indigenous context.
Aims: To explore GPs’ knowledge, attitudes and practices of managing
smoking in pregnant women.
Methods: A random sample of 500 members of the RACGP National
Faculty of Aboriginal and Torres Strait Islander Health were invited to an
on-line survey. Inclusion criteria were GPs who consult with pregnant
women. The response rate was low at 8% (N = 42), however alternative
recruitment is ongoing.
Results: One-third of the sample worked in Indigenous organisations; 62%
of respondents were women. Most GPs (81%) always asked and gave brief
advice about smoking in pregnancy. Less GPs (62%) always provided ces-
sation support, assessed dependence (55%), discussed the psychosocial
context of smoking (33%), followed up within 2 weeks (14%); 5% referred
to the Quitline. Only 21% always recommended/prescribed nicotine replace-
ment therapy (NRT), despite 93% agreeing that using NRT in pregnancy
was safer than smoking; 71% believed NRT was moderately effective, and
69% were confident to prescribe NRT. More GPs in Indigenous organisa-
tions, compared to mainstream, agreed that discussing smoking benefits
their relationship with pregnant clients (p < 0.05). Discussing psychosocial
contexts was positively associated with prescribing NRT (p < 0.05). Only
10% GPs trained in smoking cessation for pregnancy; 83% agreed training
was warranted, over two-thirds agreed access to oral NRT should be
improved.
Conclusions: Smoking cessation is a high priority for cancer prevention.
NRT can be offered to pregnant smokers unable to quit. Low levels of
assisted quitting may relate to scarcity of training for pregnancy, and policies
governing access. Caution is advised due to small sample size.
Translational research aspect: Training GPs in smoking cessation for preg-
nant women, and improving NRT access, may progress T2/3 translation of
evidence-based methods for smokers in high prevalence groups.
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Background: Smoking prevalence among Indigenous pregnant women is
four times the rate in non-Indigenous women (49% vs.12%). An evidence-
practice gap exists in evidence-based primary care approaches for Indig-
enous pregnant smokers.
Aims: To develop a culturally appropriate intervention to improve the pro-
vision of evidence-based smoking cessation care to pregnant women attend-
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